PrEP

US: Gilead CEO insists federal government patent for HIV prevention pill Truvada is invalid

The chief executive of Gilead Sciences, the nation’s leading manufacturer of HIV drugs, defended the high cost of a key drug that prevents the lethal infection, telling a House committee Thursday that its hefty profits pay for continued research.

US: AIDS activists skewer CDC for conflicting stance on collecting HIV drug royalties

Amid ongoing efforts to thwart HIV, AIDS activists are growing increasingly frustrated with the Centers for Disease Control and Prevention for failing to reach a deal with Gilead Sciences (GILD) over royalties on its sales of the Truvada prevention pill.

UK: Racism, marginalisation and PrEP stereotypes affect PrEP uptake for black MSM in London

Black men who have sex with men (MSM) in London experience a unique set of motivations and barriers to using pre-exposure prophylaxis (PrEP), according to the results of a recent qualitative study published in Sexually Transmitted Infections. This research was carried out by T. Charles Witzel and colleagues at the London School of Hygiene and Tropical Medicine.